CORE
🇺🇦
make metadata, not war
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Community governance
Advisory Board
Board of supporters
Research network
About
About us
Our mission
Team
Blog
FAQs
Contact us
research
Drug-related mutational patterns in hepatitis B virus (HBV) reverse transcriptase proteins from Iranian treatment-Naïve chronic HBV patients
Authors
F. Abedi
S.M. Alavian
+32 more
B. Ataei
T.M. Azad
M. Daram
Z. Fazeli
S. Ghamari
Z. Goodarzi
S.M. Jazayeri
M.A. Judaki
E. Kalantari
H. Karimzadeh
H. Keyvani
A. Khedive
M. Mahabadi
M. Mahmoodi
R. Malekzadeh
F. Mansour-Ghanaei
G. Montazeri
A. Moradi
A. Nejatizadeh
M. Norouzi
M.A. Pourhosseingholi
H. Rafatpanah
F. Ramezani
E. Saberfar
M. Saberfiroozi
K. Samimirad
I. Sanei-Moghaddam
G. Sarizadeh
B. Sayad
M.H. Somi
M. Yaran
M. Ziee
Publication date
1 January 2013
Publisher
'Kowsar Medical Institute'
Doi
Cite
Abstract
Background: Immunomodulators and Nucleotide analogues have been used globally for the dealing of chronic hepatitis B virus (HBV) infection. However, the development of drug resistance is a major limitation to their long-term effectiveness. Objectives: The aim of this study was to characterize the hepatitis B virus reverse transcriptase (RT) protein variations among Iranian chronic HBV carriers who did not receive any antiviral treatments. Materials and Methods: Hepatitis B virus partial RT genes from 325 chronic in active carrier patients were amplified and directly sequenced. Nucleotide/amino acid substitutions were identified compared to the sequences obtained from the database. Results: All strains belonging to genotype D.365 amino-acid substitutions were found. Mutations related to lamivudine, adefovir, telbivudine, and entecavir occurred in (YMDD) 4% (n = 13), (SVQ) 17.23% (n = 56), (M204I/V + L180M) 2.45% (n = 8) and (M204I) 2.76% (n = 9) of patients, respectively. Conclusions: RT mutants do occur naturally and could be found in HBV carriers who have never received antiviral therapy. However, mutations related to drug resistance in Iranian treatment-naïve chronic HBV patients were found to be higher than other studies published formerly. Chronic HBV patients should be monitored closely prior the commencement of therapy to achieve the best regimen option. © 2013, KOWSAR Corp
Similar works
Full text
Open in the Core reader
Download PDF
Available Versions
Golestan University of Medical Sciences Repository
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:eprints.goums.ac.ir:1908
Last time updated on 11/11/2016